ERBB2 and breast cancer: In vitro studies confirmed that conjugated trastuzumab is more effective than unconjugated trastuzumab in inhibiting colony formation in HER2-positive cells, making the RC48-ADC a potential therapeutic option in HER2-positive BC (Yaghoubi et al., 2021).